ClinicalTrials.gg
Enrolling by invitationNCT07725328mHEALTHUpdated Nov 13, 2026

Pragmatic Mobile Health Trial to Promote Cancer Screening and Healthy Behaviors

An interventional study of Intensive Engagement and Standard Engagement in Cancer Screening, Chronic Diseases in Older Adults and Early Cancer Detection, sponsored by National University Hospital, Singapore. Enrolling by invitation at 1 site in Singapore. Open to female participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Screening

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
50 Years to 69 Years
Sex
Female
01

Study summary

Cancer is the leading cause of death in Singapore, but many people who are eligible for breast, cervical, and colorectal cancer screening do not get screened on time. Many adults also have chronic health conditions such as high blood pressure, diabetes, high cholesterol, and obesity, which can often be reduced through healthier lifestyle habits. Although reminders for screening are available, they may not be enough to encourage long-term healthy behaviours.

This study will evaluate whether regular health messages delivered through a mobile health (mHealth) platform can help improve cancer screening participation and promote healthier lifestyles among Singaporean women aged 50-69 years. Participants will be randomly assigned to one of two groups. The control group will receive standard cancer screening reminders every six months. The intervention group will receive monthly evidence-based health messages, including information on cancer screening, healthy eating, physical activity, and other healthy lifestyle behaviours, delivered through the NUHS App (or a similar mobile platform) or SMS.

The study will compare whether more frequent and engaging health messages lead to higher participation in recommended cancer screening, greater engagement with the digital platform, and healthier lifestyle behaviours compared with standard reminders. The findings may help identify an effective and scalable digital approach to support cancer prevention and healthy ageing across Singapore.

Read the detailed description

Cancer remains the leading cause of death in Singapore despite the availability of national screening programmes for breast, cervical, and colorectal cancers. Participation in recommended cancer screening remains below desired levels, while chronic diseases associated with unhealthy lifestyle behaviours continue to increase. Existing approaches to promoting preventive health often rely on infrequent reminders and may be insufficient to support sustained behavioural change.

Singapore's widespread use of smartphones and digital health platforms provides an opportunity to deliver scalable mobile health (mHealth) interventions. This pragmatic randomized trial will evaluate whether regular delivery of evidence-based health messages through the NUHS App (or a similar mobile platform) or SMS can improve participation in recommended cancer screening and promote healthier lifestyle behaviours among Singaporean women aged 50-69 years.

Participants will receive either standard screening reminders or a more intensive programme of health messages covering cancer screening, healthy diet, physical activity, weight management, and other preventive health topics. The study will evaluate whether a sustained digital engagement strategy is more effective than standard reminders in encouraging long-term health behaviour change.

Because the intervention is delivered using existing healthcare digital infrastructure, the findings will inform whether this approach can be implemented at scale to improve cancer prevention and support healthy ageing in Singapore.

02

Conditions studied

  • Cancer Screening
  • Chronic Diseases in Older Adults
  • Early Cancer Detection
  • Mammography
  • Fecal Immunochemical Test
  • Colonoscopy
  • HPV Testing

Keywords

  • Mobile health technology (mhealth)
  • Healthy lifestyle behaviour
  • Behaviour intervention
  • Sustained engagement
  • Early cancer detection
  • Cancer screening
  • Behavioral intervention
03

In context

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. If using app for message delivery: Registered NUHS App users or HealthHub App users OR if using SMS for message delivery: Participants must have a mobile number recorded in electronic medical records (EPIC).
  2. Female
  3. Singapore citizen
  4. Aged 50-69 years
  5. With or without prior diagnosis of cancer

Exclusion criteria

Exclusion Criteria:

  1. Participants unable to provide and take surveys, such as those with cognitive impairments or severe mental health conditions.
  2. Participants with terminal illness or serious comorbidities that preclude them from participating in preventive health programs.
  3. Pregnant women: Given the target age group (50-69 years), the prevalence of pregnancy is expected to be extremely low.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Other
    Standard Messaging Arm (Arm 1)

    Participants receive standard cancer screening reminders through the NUHS App or SMS according to usual practice.

    Behavioral: Standard Engagement

  • Experimental
    Intensive Engagement Arm (Arm 2)

    Participants receive regular evidence-based health messages through the NUHS App or SMS to promote cancer screening and healthy lifestyle.

    Behavioral: Intensive Engagement

Interventions

  • BehavioralIntensive Engagement

    Participants will receive the standard bi-annual health messages as in Arm 1, supplemented with additional monthly messages through PN via the app OR via SMS, that provide comprehensive information on general population cancer screening guidelines, healthy lifestyle practices, motivational health messages, video links, and details about relevant events over a period of 12 months. In addition to the monthly messages, participants will be invited to attend up to 12 webinars (on women's health/screening/nutrition/lifestyle related topics) and 12 in-person or virtual group events (like simple low-intensity exercise/ walking/ basic yoga/ tai chi/nutritional cooking etc.) over 12 months. Interested participants may also be asked to join a moderated chatgroup (using Telegram app). The chatgroup is intended to promote peer support and healthy habit building.

  • BehavioralStandard Engagement

    Participants receive two standard health messages through PN via the NUHS app or similar platforms OR via SMS - one at recruitment and a subsequent reminder message after 6 months. The content will include general population cancer screening guidelines (breast, colorectal, and cervical cancers) and information pertaining to healthy lifestyle practices (including maintaining a healthy BMI, balanced diet, and sufficient exercise).

06

What researchers measure

Primary outcomes

  1. Comparison of Screen-Adherent Participants Between Arm 1 and Arm 2

    Proportion of screen-adherent participants (in %) in Arm-2 versus Arm-1 at 24 months. Non-adherence at baseline is defined as not being fully adherent to screening guidelines for all three cancers (with cervical cancer screening excluded for those not sexually active). Adherence following the intervention is defined as showing at least one improvement in adherence (e.g., previously adherent to only cervical cancer screening, with subsequent adherence to colorectal cancer screening).

    Time frame: 24 months post-intervention

Secondary outcomes

  1. Proportion of participants with BMI in the healthy range

    Proportion of participants (in %) with BMI in the healthy range (18.5-22.9 kg/m2) in Arm 1 vs Arm 2

    Time frame: 24 months post-intervention

  2. Proportion of participants achieving a daily goal of 10,000 steps

    Proportion of participants (in %) achieving a daily goal of 10,000 steps in Arm 1 vs Arm 2

    Time frame: 24 months post-intervention

  3. Proportion of participants with recommended moderate-intensity aerobic activity

    Proportion of participants (in %) with 150-300 minutes of moderate-intensity aerobic activity in Arm 1 vs Arm 2

    Time frame: 24 months post-intervention

  4. Proportion of participants eating recommended servings of fruits/vegetables daily at 24 months

    Proportion of participants eating at least 5 servings of fruits/vegetables daily in Arm 1 vs Arm 2

    Time frame: 24 months post-intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Jan 15, 2027was Sep 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Jan 15, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Sep 1, 2026→Jan 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07725328
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Soo-Chin Lee, MBBS, MRCP
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion